Pelthos Therapeutics Inc.
PTHS
Get informed when a big investor buys or sells
+ FollowMarket Cap$78.72M
Close$
$31.82
33% upside
Current Fair Value
33% upsideUndervalued by 33% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $78.72 Million |
|---|---|
| Enterprise Value | $101.13 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-23.04 |
| Beta | 3.05 |
| Outstanding Shares | 3,539,464 |
Return
| Return on Equity | 4767.29% |
|---|---|
| Return on Assets | -52.10% |
| Return on Invested Capital | -28.62% |
Valuation & Multiples
| P/E Ratio | -0.54 |
|---|---|
| PEG | -0.09 |
| Price to Sales | 1.99 |
| Price to Book Ratio | -23.92 |
| Enterprise Value to Revenue | 2.34 |
| Enterprise Value to EBIT | -3.35 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.46 |
| Debt to Equity | -31.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-2.82
Average shareholder expectationRevenue Estimate
$15.17 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-2.90
Average shareholder expectationRevenue Estimate
$17.96 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 37.38%▲ 9.84% |
|---|---|
| Total Invested | $37.39M▲ 95.08% |
| Investors Holding | 23▲ 6.00% |
ESG Score
No data
About Pelthos Therapeutics Inc.
92 employees
CEO: Scott Plesha Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medic...